drugset
Drugs / JNJ-73763989
last change Oct 2025 re-read 2 minutes ago

JNJ-73763989

also known as JNJ-3989

Small interfering RNA (siRNA)

Developed for
chronic hepatitis B virus infection · hepatitis D virus infection
Investigated by
Janssen Research & Development, LLC · Janssen Sciences Ireland UC

Trials 13 · a red edge is where a trial was stopped

today NCT05275023 · Ph 2 NCT05123599 · Ph 1 NCT05005507 · Ph 2 NCT04963738 · Ph 1 NCT04585789 · Ph 2 NCT04667104 · Ph 2 NCT04586439 · Ph 1 NCT04535544 · Ph 2 NCT04439539 · Ph 2 NCT04208386 · Ph 1 NCT04129554 · Ph 2 NCT03982186 · Ph 2 NCT04002752 · Ph 1
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT05123599 Dec 2021 → Jul 2023 chronic hepatitis B virus infection Janssen Research & Development, LLC Completed No outcome recorded
Phase 1 NCT04963738 Sep 2021 → Oct 2022 impaired renal function disease Janssen Research & Development, LLC Completed No outcome recorded
Phase 1 NCT04586439 Nov 2020 → Feb 2021 — Janssen Research & Development, LLC Completed No outcome recorded
Phase 1 NCT04208386 Jan → Jul 2020 — Janssen Sciences Ireland UC Completed No outcome recorded
Phase 1 NCT04002752 Jul → Aug 2019 — Janssen Sciences Ireland UC Completed No outcome recorded
Phase 28 trials
Phase 2 NCT05275023 Jun 2022 → Dec 2023 chronic hepatitis B virus infection Janssen Research & Development, LLC Completed No outcome recorded
Phase 2 NCT05005507 Nov → Dec 2021 chronic hepatitis B virus infection Janssen Research & Development, LLC Terminated No outcome recorded
Phase 2 NCT04585789 Mar 2021 → Feb 2023 chronic hepatitis B virus infection Janssen Research & Development, LLC Completed No outcome recorded
Phase 2 NCT04667104 Feb 2021 → May 2022 chronic hepatitis B virus infection Janssen Research & Development, LLC Completed No outcome recorded
Phase 2 NCT04535544 Sep 2020 → Oct 2023 hepatitis D virus infection Janssen Research & Development, LLC Completed No outcome recorded
Phase 2 NCT04439539 Sep 2020 → Aug 2023 chronic hepatitis B virus infection Janssen Research & Development, LLC Completed No outcome recorded
Phase 2 NCT04129554 Nov 2019 → Jul 2021 chronic hepatitis B virus infection Janssen Sciences Ireland UC Completed No outcome recorded
Phase 2 NCT03982186 Aug 2019 → Mar 2021 chronic hepatitis B virus infection Janssen Sciences Ireland UC Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 15 sources stand behind the page.

FieldValueCited text
Known as JNJ-73763989 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04667104 ↗
12

NCT05005507 ↗

NCT03982186 ↗

NCT04585789 ↗

NCT04129554 ↗

NCT05275023 ↗

NCT04535544 ↗

NCT04963738 ↗

NCT04439539 ↗

NCT04586439 ↗

NCT05123599 ↗

NCT04002752 ↗

NCT04208386 ↗
Known as JNJ-3989 “BACKGROUND & AIMS: JNJ-73763989 (JNJ-3989) is a small-interfering RNA composed of two triggers targeting the HBsAg and HBx protein open reading frame, designed to target all...” PMID 41362713 ↗ Oct 2025
3

“JNJ-73763989 (JNJ-3989) is a small interfering ribonucleic acid (siRNA) targeting all hepatitis B virus (HBV) messenger ribonucleic acid (mRNAs).” NCT05275023 ↗

“following a subcutaneous (SC) injection of JNJ-73763989 (JNJ-3989) in participants with liver cirrhosis” NCT04208386 ↗

“the small-interfering RNA JNJ-73763989 (JNJ-3989)” PMID 38583491 ↗ Apr 2024
Action Inhibit “designed to target all HBV RNAs for degradation” PMID 41362713 ↗ Oct 2025
Modality Small interfering RNA (siRNA) “JNJ-73763989 (JNJ-3989) is a small-interfering RNA composed of two triggers targeting the HBsAg and HBx protein open reading frame” PMID 41362713 ↗ Oct 2025
Route Subcutaneous “JNJ-73763989 is a liver-targeted antiviral therapeutic for subcutaneous injection” NCT03982186 ↗